<DOC>
	<DOCNO>NCT02061852</DOCNO>
	<brief_summary>The purpose study determine whether medical device `` simeox '' safe treatment respiratory disease , comparison traditional physiotherapy .</brief_summary>
	<brief_title>Evaluation Safety Medical Device SimeoxÂ®</brief_title>
	<detailed_description />
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Bronchitis , Chronic</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Ciliary Motility Disorders</mesh_term>
	<criteria>Patient 18 , male female . Patient affect bronchodegenerative disease , chronic obstructive airway disease , cystic fibrosis , idiopathic bronchiectasis , ciliary dyskinesia and/or chronic bronchitis . Hospitalization minimum five day maximum 8 day . Bronchial clearance usually productive . FVC / FEV &lt; 85 % predict , stable lung function . Agreement participate study signature inform consent form Social security coverage . Patient infect bacteria resistant antibiotic . Bronchial clearance usually productive . Patient contraindication physiotherapy bronchial clearance . Patient receive lung transplant . Care require 2 session chest physiotherapy daily . Duration mechanical ventilation &gt; 8h/day . Patient episode hemoptysis month inclusion . Patient episode pneumothorax last month . Pregnant lactating woman . Patient disability and/or unwillingness follow protocol requirement . Patient participate another clinical study test experimental drug within 30 day prior inclusion study . Patient ( ) another condition , accord investigator , may interfere result conduct trial thus justify non inclusion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>